Hillan Kenneth J.
- SEC CIK
- 0001600359
No open-market purchases or sales filed in the past year.
Current role at each company
- SGMOQ Sangamo Therapeutics, IncDirectoras of Jun 16, 2025
- ZYME Zymeworks Inc.Directoras of Dec 8, 2023
- MEHCQ Chrome Holding Co.Chief Therapeutics Officeras of Jun 7, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Hillan Kenneth J. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
MEHCQ Chrome Holding Co.
Chief Therapeutics Officer1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 25, 2022 (view filing) | Aug 24 | 1 day | Hillan Kenneth J.Chief Therapeutics Officer | SSaleClass A Common Stock | −8.75K | $3.64 | −$31.9K | −4.3%196.1K after |